Metabolism of 20-hydroxyvitamin D3 and 20,23-dihydroxyvitamin D3 by rat and human CYP24A1

CYP11A1 hydroxylates vitamin 03 producing 20S-hydroxyvitamin 03 [20(OH)D3] and 20S,23-dihydroxyvitamin D3 [20,23(OH)(2)D3] as the major and most characterized metabolites. Both display immuno-regulatory and anti-cancer properties while being non-calcemic. A previous study indicated 20 (OH)D3 can be metabolized by rat CYP24A1 to products including 205,24-dihydroxyvitamin 03 [20,24 (OH)(2)D3] and 20S,25-dihydroxyvitamin 03, with both producing greater inhibition of melanoma colony formation than 20(OH)D3. The aim of this study was to characterize the ability of rat and human CYP24A1 to metabolize 20(OH)D3 and 20,23(OH)(2)D3. Both isoforms metabolized 20(OH)D3 to the same dihydroxyvitamin D species with no secondary metabolites being observed. Hydroxylation at C24 produced both enantiomers of 20,24(OH)(2)D3. For rat CYP24A1 the preferred initial site of hydroxylation was at C24 whereas the human enzyme preferred C25. 20,23(OH)(2)D3 was initially metabolized to 20S,23,24-trihydroxyvitamin D3 and 20.5,23,25-trihydroxyvitamin D3 by rat and human CYP24A1 as determined by NMR, with both isoforms showing a preference for initial hydroxylation at C25. CYP24A1 was able to further oxidize these metabolites in a series of reactions which included the cleavage of C23-C24 bond, as indicated by high resolution mass spectrometry of the products, analogous to the catabolism of 1,25(OH)(2)D3 via the C24-oxidation pathway. Similar catalytic efficiencies were observed for the metabolism of 20(OH)D3 and 20,23(OH)(2)D3 by human CYP24A1 and were lower than for the metabolism of 1,25(OH)(2)D3. We conclude that rat and human CYP24A1 metabolizes 20(OH) 03 producing only dihydroxyvitamin D3 species as products which retain biological activity, whereas 20,23(OH)(2)D3 undergoes multiple oxidations which include cleavage of the side chain. (C) 2015 Elsevier Ltd. All rights reserved.